- Home
- SNX vs INM Comparison
SNX vs INM Comparison
Compare SNX & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNX
- INM
- Stock Information
- Founded
- SNX 1980
- INM 1981
- Country
- SNX United States
- INM Canada
- Employees
- SNX N/A
- INM N/A
- Industry
- SNX Retail: Computer Software & Peripheral Equipment
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- SNX Technology
- INM Health Care
- Exchange
- SNX Nasdaq
- INM Nasdaq
- Market Cap
- SNX 13.3B
- INM 5.0M
- IPO Year
- SNX 2003
- INM N/A
- Fundamental
- Price
- SNX $150.75
- INM $1.73
- Analyst Decision
- SNX Strong Buy
- INM
- Analyst Count
- SNX 10
- INM 0
- Target Price
- SNX $169.00
- INM N/A
- AVG Volume (30 Days)
- SNX 545.4K
- INM 98.7K
- Earning Date
- SNX 09-25-2025
- INM 11-13-2025
- Dividend Yield
- SNX 1.17%
- INM N/A
- EPS Growth
- SNX 18.98
- INM N/A
- EPS
- SNX 9.21
- INM N/A
- Revenue
- SNX $60,973,509,000.00
- INM $4,942,633.00
- Revenue This Year
- SNX $7.25
- INM N/A
- Revenue Next Year
- SNX $4.50
- INM N/A
- P/E Ratio
- SNX $16.40
- INM N/A
- Revenue Growth
- SNX 6.94
- INM 7.50
- 52 Week Low
- SNX $92.23
- INM $1.71
- 52 Week High
- SNX $167.76
- INM $8.27
- Technical
- Relative Strength Index (RSI)
- SNX 41.20
- INM 28.07
- Support Level
- SNX $153.63
- INM $1.80
- Resistance Level
- SNX $159.36
- INM $1.92
- Average True Range (ATR)
- SNX 3.12
- INM 0.11
- MACD
- SNX -0.46
- INM -0.03
- Stochastic Oscillator
- SNX 19.23
- INM 10.09
About SNX TD SYNNEX Corporation
TD Synnex Corp is a distributor and solutions aggregator for the IT ecosystem. The company aggregates and distributes IT hardware, software, and systems including personal computing devices and peripherals, mobile phones and accessories, printers, server and data center infrastructure, hybrid cloud, security, networking, communications and storage solutions, and system components. Its geographical segments include the Americas, Europe, and APJ.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.